Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC
Keywords: Alimta; Docetaxel; EGFR; EGFR-TKI; Erlotinib; Gefitinib; Iressa; NSCLC; Pemetrexed; Tarceva; Taxotere; adenocarcinoma; cetaxel; docetaxel; dyspnea; erlotinib; pemetrexed; pemetrexed erlotinib gefitinib; platinum-based chemotherapy; tyrosine kinase inhibitor; vascular endothelial growth factor (VEGF)
Document Type: Research Article
Publication date: January 1, 2011
- Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites